Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro.

Gholami YH, Willowson KP, Forwood NJ, Harvie R, Hardcastle N, Bromley R, Ryu H, Yuen S, Howell VM, Kuncic Z, Bailey DL.

EJNMMI Phys. 2018 Sep 3;5(1):18. doi: 10.1186/s40658-018-0217-8.

2.

Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs.

Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, Schultz M.

World J Gastroenterol. 2017 Jul 7;23(25):4632-4643. doi: 10.3748/wjg.v23.i25.4632.

3.

Using the Human Gastrointestinal Microbiome to Personalize Nutrition Advice: Are Registered Dietitian Nutritionists Ready for the Opportunities and Challenges?

Harvie R, Chanyi RM, Burton JP, Schultz M.

J Acad Nutr Diet. 2017 Dec;117(12):1865-1869. doi: 10.1016/j.jand.2016.10.020. Epub 2016 Dec 13. No abstract available.

PMID:
27986518
4.

"We are what our bacteria eat": The role of bacteria in personalizing nutrition therapy in gastrointestinal conditions.

Harvie R, Walmsley R, Schultz M; New Zealand Society of Gastroenterology.

J Gastroenterol Hepatol. 2017 Feb;32(2):352-357. doi: 10.1111/jgh.13462. Review.

PMID:
27248703
5.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.

PMID:
25701452
6.

Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.

Hudson AL, Weir C, Moon E, Harvie R, Klebe S, Clarke SJ, Pavlakis N, Howell VM.

Sci Rep. 2014 Aug 21;4:6152. doi: 10.1038/srep06152.

7.

Health-related quality of life and inflammatory markers in malignant pleural mesothelioma.

Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S, Pavlakis N.

Support Care Cancer. 2013 Mar;21(3):697-705. doi: 10.1007/s00520-012-1569-6. Epub 2012 Aug 31.

PMID:
22936495
8.

The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N.

Lung Cancer. 2012 Feb;75(2):248-54. doi: 10.1016/j.lungcan.2011.06.007. Epub 2011 Jul 16.

PMID:
21757252
9.

High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ.

Clin Cancer Res. 2010 Dec 1;16(23):5805-13. doi: 10.1158/1078-0432.CCR-10-2245. Epub 2010 Oct 18.

10.

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.

Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G.

Ann Oncol. 2010 Jun;21(6):1302-7. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.

PMID:
19917571
11.

Predicting the clonogenic survival of A549 cells after modulated x-ray irradiation using the linear quadratic model.

Bromley R, Oliver L, Davey R, Harvie R, Baldock C.

Phys Med Biol. 2009 Jan 21;54(2):187-206. doi: 10.1088/0031-9155/54/2/002. Epub 2008 Dec 16.

PMID:
19088388
12.

A preliminary investigation of cell growth after irradiation using a modulated x-ray intensity pattern.

Bromley R, Davey R, Oliver L, Harvie R, Baldock C.

Phys Med Biol. 2006 Aug 7;51(15):3639-51. Epub 2006 Jul 12.

PMID:
16861771
13.

Changes in gene expression associated with stable drug and radiation resistance in small cell lung cancer cells are similar to those caused by a single X-ray dose.

Henness S, Davey MW, Harvie RM, Banyer J, Wasinger V, Corthals G, Davey RA.

Radiat Res. 2004 May;161(5):495-503.

PMID:
15161375
14.

Cellular models of drug- and radiation-resistant small cell lung cancer.

Davey RA, Locke VL, Henness S, Harvie RM, Davey MW.

Anticancer Res. 2004 Mar-Apr;24(2A):465-71.

15.
16.

Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublines.

O'Neill GM, Peters GB, Harvie RM, MacKenzie HB, Henness S, Davey RA.

Br J Cancer. 1998 Jun;77(12):2076-80.

18.

The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.

Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW.

Cancer Chemother Pharmacol. 1997;39(5):424-30.

PMID:
9054956
19.
20.

Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line.

Davey RA, Longhurst TJ, Davey MW, Belov L, Harvie RM, Hancox D, Wheeler H.

Leuk Res. 1995 Apr;19(4):275-82.

PMID:
7752673
21.
22.

Detection of mRNA for ribosomal phosphoprotein P2 in normal colon and colonic tumours by in situ hybridization.

Harvie R, Elvin P, McArdle C, Morten JE, McNicol AM.

J Pathol. 1991 May;164(1):67-73.

PMID:
2056390
23.

Detection of messenger RNA using a digoxigenin end labelled oligodeoxynucleotide probe.

Farquharson M, Harvie R, McNicol AM.

J Clin Pathol. 1990 May;43(5):424-8.

24.

Serum galactosyltransferase as a prognostic marker in patients with solid tumors.

Davey RA, Milliken ST, Harvie RM, Cahill EJ, Morgan LJ, Kerestes Z, Levi JA.

Cancer Res. 1986 Nov;46(11):5973-5.

25.

Serum galactosyltransferase isoenzyme patterns of cancer patients with liver involvement.

Davey R, Harvie R, Cahill J, Levi J.

Br J Cancer. 1986 Feb;53(2):211-5.

26.

The heterogeneity and acceptor specificity of human serum galactosyltransferase.

Davey R, Harvie R, Cahill J.

Biochem Int. 1984 May;8(5):687-96.

PMID:
6433936
27.

Serum galactosyltransferase isoenzymes as markers for solid tumours in humans.

Davey RA, Harvie RM, Cahill EJ, Levi JA.

Eur J Cancer Clin Oncol. 1984 Jan;20(1):75-9.

PMID:
6420160
28.

Adverse effects of commonly used systemic drugs on the human eye. Part III.

Silverman HI, Harvie RJ.

Am J Optom Physiol Opt. 1975 Apr;52(4):275-87.

PMID:
1130492
29.

Dicephalus dipus dibrachius--case study.

Harvie R.

Nurs Mirror Midwives J. 1970 Oct 9;131(15):23-5. No abstract available.

PMID:
5203261
30.

Travelling-wave linear accelerator for electrons.

FRY DW, HARVIE RB, et al.

Nature. 1947 Sep 13;160(4063):351-3. No abstract available.

PMID:
20263964
31.

Retained Placenta; Expectant Treatment Successful.

Harvie RM.

Can Med Assoc J. 1924 Jan;14(1):65. No abstract available.

Supplemental Content

Loading ...
Support Center